Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Countering Development of Resistance to Treatment in AML By Targeting Metabolic Adaptations

Marta Romo-González, Tanima Kundu, M. Elena Diaz-Rubio, Xiaoyang Su, Matthew J McBride, Christina Glytsou

Blood (2024) 144 (Supplement 1): 5748.

https://doi.org/10.1182/blood-2024-211612

Published: 2024

Journal Articles

Radioimmunotherapy of Non-Hodgkin Lymphoma is Improved without Increasing Toxicity by Combination with Antibody immunotherapy.

Robert M Sharkey, Ph.D., M. Jules Mattes, Ph.D., Habibe Karacay, Ph.D., Chien-Hsing Chang, PhD, Edmund A Rossi, PhD, William J McBride, Ph.D., David M. Goldenberg, ScD, MD

Blood (2008) 112 (11): 1588.

https://doi.org/10.1182/blood.V112.11.1588.1588

Published: 2008

Journal Articles

Improved Responses and Cures with Less Hematologic Toxicity Using Anti-CD20 Bispecific Antibody Pretargeted Radionuclides Compared to Directly Radiolabeled IgG in a NHL Model.

David M. Goldenberg, ScD, MD, Robert M. Sharkey, PhD, Habibe Karacay, PhD, Chien-Hsing Chang, PhD, Edmund A. Rossi, PhD, William J. McBride, PhD

Blood (2007) 110 (11): 2344.

https://doi.org/10.1182/blood.V110.11.2344.2344

Published: 2007

Journal Articles

A New Class of Dimeric α-Interferons (IFN-α) Made by the Dock and Lock (DNL) Method for Improved Cancer Therapy.

Edmund A. Rossi, PhD, William J. McBride, Ph.D., Diane L. Nordstrom, M.S., Preeti Trisal, M.S., Thomas M. Cardillo, Ph.D., David M. Goldenberg, M.D. Sc.D., Chien-Hsing Chang, Ph.D.

Blood (2007) 110 (11): 1396.

https://doi.org/10.1182/blood.V110.11.1396.1396

Published: 2007

Journal Articles

Eosinophils from patients with blood eosinophilia express transforming growth factor beta 1

DT Wong, A Elovic, K Matossian, N Nagura, J McBride, MY Chou, JR Gordon, TH Rand, SJ Galli, PF Weller

Blood (1991) 78 (10): 2702–2707.

https://doi.org/10.1182/blood.V78.10.2702.2702

Published: 1991

NARROW

Countering Development of Resistance to Treatment in AML By Targeting Metabolic Adaptations

Radioimmunotherapy of Non-Hodgkin Lymphoma is Improved without Increasing Toxicity by Combination with Antibody immunotherapy.

Improved Responses and Cures with Less Hematologic Toxicity Using Anti-CD20 Bispecific Antibody Pretargeted Radionuclides Compared to Directly Radiolabeled IgG in a NHL Model.

A New Class of Dimeric α-Interferons (IFN-α) Made by the Dock and Lock (DNL) Method for Improved Cancer Therapy.

Eosinophils from patients with blood eosinophilia express transforming growth factor beta 1

Email alerts

ASH Publications

American Society of Hematology

Countering Development of Resistance to Treatment in AML By Targeting Metabolic Adaptations

Radioimmunotherapy of Non-Hodgkin Lymphoma is Improved without Increasing Toxicity by Combination with Antibody immunotherapy.

Improved Responses and Cures with Less Hematologic Toxicity Using Anti-CD20 Bispecific Antibody Pretargeted Radionuclides Compared to Directly Radiolabeled IgG in a NHL Model.

A New Class of Dimeric α-Interferons (IFN-α) Made by the Dock and Lock (DNL) Method for Improved Cancer Therapy.

Eosinophils from patients with blood eosinophilia express transforming growth factor beta 1

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only